Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.incyte.com
Incyte Corporation News Releases
Get the latest updates from Incyte Corporation News Releases directly as they happen.
Follow now 177 followers
Latest posts
Last updated 2 days ago
Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
2 days ago
– Total revenues of $1,216 million in the second quarter (Q2'25) (+16%...
Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025
6 days ago
- Mini oral presentation to highlight initial Phase 1 data of INCA33890...
Incyte to Report Second Quarter Financial Results
21 days ago
WILMINGTON, Del. --(BUSINESS WIRE)--Jul. 10, 2025-- Incyte (Nasdaq:INCY) announced today that it...
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
28 days ago
WILMINGTON, Del. --(BUSINESS WIRE)--Jul. 2, 2025-- Incyte Corporation (Nasdaq: INCY) announced today...
Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire
about 1 month ago
- Three-decade industry leader, former CEO of Karuna and Anthos and Chief...
Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis
about 1 month ago
WILMINGTON, Del. --(BUSINESS WIRE)--Jun. 20, 2025-- Incyte (Nasdaq: INCY) today announced that...
Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
about 1 month ago
- Monjuvi® (tafasitamab-cxix) in combination with rituximab and lenalidomide is the first...
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
about 2 months ago
QIAGEN to create a multimodal panel using next-generation sequencing (NGS) technology for...
Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
about 2 months ago
Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting...
Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet
about 2 months ago
POD1UM-303/InterAACT 2 is the first and largest global Phase 3 trial evaluating...
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
about 2 months ago
WILMINGTON, Del. --(BUSINESS WIRE)--Jun. 6, 2025-- Incyte (Nasdaq:INCY) today announced that it...
Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025
about 2 months ago
Late-breaking oral presentation will highlight new data from a trial of INCA033989...